Elizabeth A. Harrington Translational Medicine, R&D Oncology AstraZeneca Biography Publications Institution JoVE Articles Elizabeth A. Harrington has not added a biography. If you are Elizabeth A. Harrington and would like to personalize this page please email our Author Liaison for assistance. Publications Proliferation Tumour Marker Network (PTM-NET) for the Identification of Tumour Region in Ki67 Stained Breast Cancer Whole Slide Images Scientific Reports. 09, 2019 | Pubmed ID: 31492872 Optimisation of Robust Singleplex and Multiplex Droplet Digital PCR Assays for High Confidence Mutation Detection in Circulating Tumour DNA Scientific Reports. 09, 2019 | Pubmed ID: 31477768 A Phase II Study to Assess the Safety and Efficacy of the Dual MTORC1/2 Inhibitor Vistusertib in Relapsed, Refractory DLBCL Hematological Oncology. Oct, 2019 | Pubmed ID: 31385336 Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Cancer Discovery. 10, 2019 | Pubmed ID: 31315834 PRAD50: a Novel and Clinically Applicable Pharmacodynamic Biomarker of Both ATM and ATR Inhibition Identified Using Mass Spectrometry and Immunohistochemistry British Journal of Cancer. 11, 2018 | Pubmed ID: 30385821 Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 12, 2018 | Pubmed ID: 30082476 Functional Significance of Co-occurring Mutations in and in Breast Cancer Oncotarget. Apr, 2018 | Pubmed ID: 29765551 Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Mar, 2017 | Pubmed ID: 27733477 Nucleic Acid Extraction from Formalin-fixed Paraffin-embedded Cancer Cell Line Samples: a Trade off Between Quantity and Quality? BMC Clinical Pathology. 2016 | Pubmed ID: 28649177 Characterization of FGFR1 Locus in SqNSCLC Reveals a Broad and Heterogeneous Amplicon PloS One. 2016 | Pubmed ID: 26905262 Evaluating Robustness and Sensitivity of the NanoString Technologies NCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples Cancer Research. Jul, 2015 | Pubmed ID: 26069246 First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual M-TORC 1/2 Inhibitor AZD2014 Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2015 | Pubmed ID: 25805799 Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel Molecular Cancer Therapeutics. Jan, 2015 | Pubmed ID: 25398829 Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString NCounter System Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. May, 2015 | Pubmed ID: 25301847 Preparação de pelotas de células mononucleares de sangue periférico e plasma de uma única coleta de sangue em locais de ensaio clínico para análise de biomarcadores Paola Marco-Casanova1, Natalia Lukashchuk1, Benedetta Lombardi1, Veerendra Munugalavadla2, Melanie M. Frigault3, Elizabeth A. Harrington1, J. Carl Barrett3, Andrew J. Pierce1 1Translational Medicine, R&D Oncology, AstraZeneca, 2Acerta Pharma, AstraZeneca Group, 3Translational Medicine, R&D Oncology, AstraZeneca JoVE 60776 医学
Preparação de pelotas de células mononucleares de sangue periférico e plasma de uma única coleta de sangue em locais de ensaio clínico para análise de biomarcadores Paola Marco-Casanova1, Natalia Lukashchuk1, Benedetta Lombardi1, Veerendra Munugalavadla2, Melanie M. Frigault3, Elizabeth A. Harrington1, J. Carl Barrett3, Andrew J. Pierce1 1Translational Medicine, R&D Oncology, AstraZeneca, 2Acerta Pharma, AstraZeneca Group, 3Translational Medicine, R&D Oncology, AstraZeneca JoVE 60776 医学